NCM is delighted that, for the first time, the Nobel Prize for chemistry has been awarded to two women in the same year. Professor Emmanuelle Charpentier, co-founder of Abingworth portfolio company CRISPR Therapeutics and Professor Jennifer Doudna of the University of California, Berkeley and the Howard Hughes Medical Institute have been awarded the prestigious prize.
We congratulate both women on becoming Nobel Laureates for their outstanding contribution to the discovery of CRISPR/Cas9 gene-editing system. This ground-breaking science is paving the way for a new generation of medical treatments which focuses on developing transformative gene-based medicines with the potential to cure serious human diseases. Abingworth first invested in CRISPR Therapeutics in 2015 and maintains a holding in the company today and is an investment in one of the funds NCM administer.
Find out more about the women here